💸 The Tape

While much of the Canadian cannabis sector spends its time explaining why the quarter was disappointing, Cannara Biotech keeps quietly doing something unusual: growing.

The Québec-based vertically integrated producer reported Q2 2026 financial results that won't make anyone's jaw drop — but in an industry where profitability remains elusive for most operators, consistent, disciplined execution is its own kind of headline.

The Numbers

Total net revenues came in at $27.2 million, up 2% year-over-year from $26.6 million. Gross cannabis revenues before excise taxes rose 3% to $37.8 million, driven by a $2.5 million (7%) increase in retail revenues that more than offset a $1.4 million decline in wholesale. That retail growth is particularly notable given that national cannabis retail sales were essentially flat over the same period — meaning Cannara is taking share, not just riding a rising tide.

Gross profit before fair value adjustments climbed 7% to $11.6 million, with margins improving to 43% from 41% a year ago — a reflection of increased production capacity and ongoing optimization across cultivation and post-processing. Adjusted EBITDA landed at $6.0 million, down from $7.1 million in the prior year quarter, as the company invested more heavily in sales and marketing, R&D, and talent to support its next growth phase.

The real story on the cash flow line: operating cash flow swung to a positive $2.9 million, a dramatic improvement from negative $2.6 million in Q2 2025. Free cash flow improved to negative $0.3 million — nearly breakeven — despite $3.2 million in capital expenditures, most of it related to the ongoing Valleyfield facility construction.

Net income totaled $1.7 million, or $0.02 per share.

The Sequential Dip — And Why It Doesn't Tell the Full Story

Quarter-over-quarter, the numbers stepped back. Total net revenues fell 10% from Q1's $30.1 million, and gross cannabis revenues declined from $41.8 million to $37.8 million. That looks concerning in isolation, but management attributes the drop to normal post-holiday seasonality in provincial board purchasing patterns — particularly in Québec — along with a normalization of vape sales following their initial launch period and softer wholesale volumes.

The key evidence that consumer demand didn't actually weaken: while the overall Canadian cannabis retail market declined 4% quarter-over-quarter, Cannara's in-market retail sales grew 5%. That divergence pushed the company's estimated national retail market share from 4.1% in Q1 to 4.4% in Q2. You don't gain share in a contracting market by accident.

Québec Dominance

The province that Cannara calls home is also where it's become the undisputed leader. The company captured an estimated 14.3% retail market share in Québec during Q2, making it the No. 1 cannabis company in the province by retail sales. For a market that operates through the SQDC — Québec's government-run retail monopoly — earning the top spot requires consistently delivering product that consumers actively seek out on shelves where brand loyalty is hard-won.

That Québec strength is the engine, but Cannara is expanding beyond its home base. Ontario market share climbed from 3.1% to 3.7% as of March 2026, and gains were recorded in British Columbia, Saskatchewan, and Manitoba as well. The company maintained stable positioning in Nova Scotia and Newfoundland. It's a national expansion playbook built on the kind of provincial-by-provincial grinding that doesn't make for splashy headlines but builds durable market position.

Product Innovation Driving the Gains

Cannara's market share trajectory isn't solely a pricing story — though the company's positioning as a producer of "premium-grade cannabis at affordable prices" certainly helps. The portfolio continues to evolve through disciplined innovation in the categories where growth is actually happening.

In infused pre-rolls — one of the fastest-growing segments in Canadian cannabis — the company launched Porto Leche Trifecta under its Tribal brand and introduced Flavour Bomb, a new liquid diamond sub-brand under Nugz, debuting with the Fruit Blast Taster Pack. Since launch, that product has consistently ranked among the top three infused pre-roll products by wholesale sales in Ontario. Cannara plans to expand the Flavour Bomb platform through the rest of Fiscal 2026.

On the cultivation side, the company's pheno-hunting program — screening hundreds of phenotypes for potency, yield, brand fit, and market appeal — yielded new genetics including Gran Turismo under Tribal and Florida Oranges under Nugz. The current fiscal year's pheno-hunt remains underway and is expected to feed a pipeline of exotic genetics for Fiscal 2027 launches.

Year-to-Date Perspective

Zoom out to the six-month view and the growth story sharpens. YTD gross cannabis revenues jumped 11% to $79.6 million, powered by a $8.3 million (12%) increase in retail sales. Total net revenues rose 11% to $57.3 million. Gross margins expanded from 40% to 44%, and adjusted EBITDA climbed 14% to $14.9 million.

YTD operating cash flow hit $10.9 million, up from just $3.3 million in the prior year period. Free cash flow reached $3.1 million despite capital expenditures more than tripling to $7.9 million — almost entirely driven by the Valleyfield buildout that will underpin Cannara's next phase of capacity-driven growth.

The Takeaway

Cannara isn't trying to be everything to everyone. It's a Québec-rooted operator with a clear playbook: produce quality cannabis efficiently at scale, price it accessibly, innovate in the categories that are growing, and expand nationally one province at a time. The Q2 results show a company executing that strategy with the kind of financial discipline — positive operating cash flow, improving margins, rising market share — that much of the Canadian cannabis industry still aspires to.

In a sector that's produced more cautionary tales than success stories, Cannara's biggest accomplishment might be the most understated one: it's boring in all the right ways.

📈 Dog Walkers

$CBWTF ( ▲ 6.22% ) Launches Major Buy Back Program

The Canadian cannabis company has announced a normal course issuer bid (NCIB) approved by the Toronto Stock Exchange, authorizing the purchase of up to 68.9 million common shares for cancellation on the open market. That figure represents just under 5% of Auxly's outstanding shares as of April 7, 2026. The buyback window runs from April 20, 2026 through April 19, 2027.

The rationale is one investors have heard before, but it carries weight when a company actually follows through: Auxly believes its market price doesn't adequately reflect its underlying value and prospects, and that repurchasing shares at current levels is a smart use of capital that will enhance shareholder value.

Daily purchases are capped at roughly 206,920 shares on the TSX, based on the stock's average daily trading volume of about 827,683 shares over the six months ending March 31. The company has also established an automatic share purchase plan (ASPP) with a designated broker, allowing buybacks to continue during blackout periods or other windows when Auxly would normally be restricted from purchasing.

All repurchased shares will be cancelled, not warehoused — meaning the buyback directly reduces the company's share count and concentrates ownership for remaining shareholders. The program will be funded entirely from existing cash resources.

With over 1.4 billion shares outstanding and a public float north of 1 billion, Auxly's capital structure is diluted by any standard. A buyback of this scale won't transform that picture overnight, but it signals that management sees the current valuation as disconnected from fundamentals — and is willing to deploy capital to close the gap rather than simply talk about it.

$RWBYF ( 0.0% ) Wins Ayurcann Bid

One company's insolvency is another company's expansion opportunity.

Red White & Bloom Brands has announced that its subsidiary Emblem Cannabis Corporation has been selected as the winning bidder in the court-supervised sale of Ayurcann Holdings Corp., which entered creditor protection under the CCAA back in January 2026. The deal, structured as a share purchase, gives Emblem ownership of 100% of newly issued Ayurcann shares — and with them, a significant boost to RWB's Canadian footprint.

The acquisition brings a considerable haul. Emblem picks up Ayurcann's brand portfolio — including Fuego, Xplor, and Happy & Stoned — spanning over 90 tracked SKUs available through approximately 2,500 retail locations across Canada, with particular strength in the fast-growing vape and pre-roll categories. Also included: Ayurcann's Health Canada-licensed processing facility in Pickering, Ontario, along with all commercial relationships, supply arrangements across eight provinces and territories, and existing inventory and equipment.

RWB President Colby De Zen called the transaction "highly strategic," emphasizing that it immediately scales the company's Canadian platform with national distribution, leading product categories, and meaningful synergies across supply chain, manufacturing, and overhead.

The deal emerged from a formal Sale and Investment Solicitation Process (SISP) approved by the Ontario Superior Court of Justice in February 2026, with Alvarez & Marsal Canada serving as court-appointed monitor. Emblem submitted a binding bid, was selected as the successful purchaser, and expects to close the transaction — subject to court approval and customary conditions — by May 15, 2026. The purchase price will be paid in cash at closing.

For RWB, the Ayurcann pickup is a textbook distressed acquisition: proven brands, real infrastructure, and national reach — all acquired at what insolvency pricing tends to deliver.

🗞️ The News

📺 YouTube

Virginia Amendment + MSOs Face New Reality in 2026 | TTB Presented by Flowhub

What we will cover:

✅ In the latest Trade To Black podcast presented by Flowhub, hosts Shadd Dales and Anthony Varrell sit down with Anthony Coniglio, CEO of NewLake Capital Partners (OTCQB: NLCP), for a high-level conversation that cuts straight through where the cannabis industry actually stands today.

This episode connects two sides of the story investors need to understand right now — policy shifts and real company performance.

On the policy front, Massachusetts is moving to expand dispensary caps and restructure its Cannabis Control Commission, signaling a push toward consolidation in a mature market. Meanwhile, Virginia is still on track for adult-use, but with a slower rollout and tighter controls, reinforcing that execution and patience matter just as much as market entry.

On the business side, the conversation breaks down what the latest earnings from major U.S. operators are really telling us. Names like Green Thumb (CSE: GTII / OTCQX: GTBIF), Trulieve (CSE: TRUL / OTCQX: TCNNF), Curaleaf (TSX: CURA / OTCQX: CURLF), Cresco Labs (CSE: CL / OTCQX: CRLBF), Glass House Brands (CSE: GLAS / OTCQX: GLASF), and Jushi Holdings (CSE: JUSH / OTCQX: JUSHF) are no longer being judged on growth alone — it’s about margins, cash flow, and balance sheet strength.